These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2327116)

  • 61. Treatment with digoxin and measurement of serum digoxin levels after myocardial infarction.
    Sharpe DN; Norris RM; McL White B
    Br Heart J; 1975 May; 37(5):530-3. PubMed ID: 1137662
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The bioavailability of digoxin.
    Lancet; 1972 Aug; 2(7772):311-2. PubMed ID: 4115037
    [No Abstract]   [Full Text] [Related]  

  • 63. Pharmacokinetics, bioavailability, and dosage regimens of digoxin in dogs.
    Button C; Gross DR; Johnston JT; Yakatan GJ
    Am J Vet Res; 1980 Aug; 41(8):1230-7. PubMed ID: 7447117
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bioavailability of drugs: the digoxin dilemma.
    Greenblatt DJ; Smith TW; Koch-Weser J
    Clin Pharmacokinet; 1976; 1(1):36-51. PubMed ID: 797491
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fasting and postprandial absorption of digoxin from a microencapsulated formulation.
    Bergdahl B; Bogentoft C; Jonsson UE; Magnusson JO
    Eur J Clin Pharmacol; 1983; 25(2):207-10. PubMed ID: 6628502
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers.
    Shah J; Wesnes KA; Kovelesky RA; Henney HR
    Clin Ther; 2006 Sep; 28(9):1308-17. PubMed ID: 17062304
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Variation in the biological availability of digoxin.
    Shaw TR; Howard MR; Hamer J
    Lancet; 1972 Aug; 2(7772):303-7. PubMed ID: 4115034
    [No Abstract]   [Full Text] [Related]  

  • 68. Relationship between plasma concentration and dose of digoxin in patients with and without renal impairment.
    Okada RD; Hager WD; Graves PE; Mayersohn M; Perrier DG; Marcus FI
    Circulation; 1978 Dec; 58(6):1196-203. PubMed ID: 709776
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Clinical study on digoxin tablets with high bioavailability (author's transl)].
    Flasch CI; Heinz N
    Arzneimittelforschung; 1979; 29(6):961-4. PubMed ID: 582792
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.
    Nikolova Z; Peng B; Hubert M; Sieberling M; Keller U; Ho YY; Schran H; Capdeville R
    Cancer Chemother Pharmacol; 2004 May; 53(5):433-8. PubMed ID: 15132131
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of the concomitant administration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin) in normal healthy subjects: a placebo-controlled evaluation.
    Miyazawa Y; Paul Starkey L; Forrest A; Schentag JJ; Kamimura H; Swarz H; Ito Y
    J Clin Pharm Ther; 2002 Feb; 27(1):13-9. PubMed ID: 11846858
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Diclofenac potassium 12.5 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative, bioavailability study versus diclofenac potassium 12.5 mg tablets.
    Kienzler JL; Gold M
    Int J Clin Pharmacol Ther; 2012 Jun; 50(6):438-44. PubMed ID: 22677305
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Digoxin compliance in patients from general practice.
    Johnston GD; McDevitt DG
    Br J Clin Pharmacol; 1978 Oct; 6(4):339-43. PubMed ID: 698030
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Non-equivalent digoxin tablets.
    Karjalainen J; Ojala K; Reissell P
    Ann Clin Res; 1974 Jun; 6(3):132-6. PubMed ID: 4844123
    [No Abstract]   [Full Text] [Related]  

  • 75. Does the frequency of daily dosage influence compliance with digoxin therapy?
    Taggart AJ; Johnston GD; McDevitt DG
    Br J Clin Pharmacol; 1981 Jan; 11(1):31-4. PubMed ID: 7213506
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40.
    Tayrouz Y; Ding R; Burhenne J; Riedel KD; Weiss J; Hoppe-Tichy T; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2003 May; 73(5):397-405. PubMed ID: 12732840
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Letter: Improving the bioavailability of digoxin.
    Binnion PF; Klopp RW
    Lancet; 1975 Jun; 1(7922):1422-3. PubMed ID: 49581
    [No Abstract]   [Full Text] [Related]  

  • 78. Comparison of medigoxin and digoxin in the control of atrial fibrillation.
    Coburn P; Kongola GM; Mawer GE
    Br J Clin Pharmacol; 1979 Jul; 8(1):53-8. PubMed ID: 552298
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Absorption of beta-methyl-digoxin determined after a single dose and under steady state conditions.
    Boerner D; Olcay A; Schaumann W; Weiss W
    Eur J Clin Pharmacol; 1976 Feb; 9(4):307-14. PubMed ID: 971714
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.
    Hull MW; Harris M; Lima V; Guillemi S; Harrigan PR; Montaner JS
    J Clin Pharmacol; 2009 Feb; 49(2):155-61. PubMed ID: 19179294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.